Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett esophagus and esophageal adenocarcinoma.

Orloff M, Peterson C, He X, Ganapathi S, Heald B, Yang YR, Bebek G, Romigh T, Song JH, Wu W, David S, Cheng Y, Meltzer SJ, Eng C.

JAMA. 2011 Jul 27;306(4):410-9. doi: 10.1001/jama.2011.1029.

2.

Genes of the interleukin-18 pathway are associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma.

Babar M, Ryan AW, Anderson LA, Segurado R, Turner G, Murray LJ, Murphy SJ, Johnston BT, Comber H, Reynolds JV, McManus R.

Am J Gastroenterol. 2012 Sep;107(9):1331-41. doi: 10.1038/ajg.2012.134. Epub 2012 Jun 5.

PMID:
22664470
3.

Germline mutations of the MSR1 gene in prostate cancer families from Germany.

Maier C, Vesovic Z, Bachmann N, Herkommer K, Braun AK, Surowy HM, Assum G, Paiss T, Vogel W.

Hum Mutat. 2006 Jan;27(1):98-102.

PMID:
16287155
4.

Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's esophagus.

Streppel MM, Lata S, DelaBastide M, Montgomery EA, Wang JS, Canto MI, Macgregor-Das AM, Pai S, Morsink FH, Offerhaus GJ, Antoniou E, Maitra A, McCombie WR.

Oncogene. 2014 Jan 16;33(3):347-57. doi: 10.1038/onc.2012.586. Epub 2013 Jan 14.

5.

Genome-wide tracts of homozygosity and exome analyses reveal repetitive elements with Barrets esophagus/esophageal adenocarcinoma risk.

Wanchai V, Jin J, Bircan E, Eng C, Orloff M.

BMC Bioinformatics. 2019 Mar 14;20(Suppl 2):98. doi: 10.1186/s12859-019-2622-y.

6.

Association Between Germline Mutation in VSIG10L and Familial Barrett Neoplasia.

Fecteau RE, Kong J, Kresak A, Brock W, Song Y, Fujioka H, Elston R, Willis JE, Lynch JP, Markowitz SD, Guda K, Chak A.

JAMA Oncol. 2016 Oct 1;2(10):1333-1339. doi: 10.1001/jamaoncol.2016.2054.

7.

Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma.

Xu E, Gu J, Hawk ET, Wang KK, Lai M, Huang M, Ajani J, Wu X.

Carcinogenesis. 2013 Dec;34(12):2750-6. doi: 10.1093/carcin/bgt286. Epub 2013 Aug 29. Erratum in: Carcinogenesis. 2014 Mar;35(3):738.

8.

Whole genome expression array profiling highlights differences in mucosal defense genes in Barrett's esophagus and esophageal adenocarcinoma.

Nancarrow DJ, Clouston AD, Smithers BM, Gotley DC, Drew PA, Watson DI, Tyagi S, Hayward NK, Whiteman DC; Australian Cancer Study; Study of Digestive Health.

PLoS One. 2011;6(7):e22513. doi: 10.1371/journal.pone.0022513. Epub 2011 Jul 28.

9.

Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma.

Akagi T, Ito T, Kato M, Jin Z, Cheng Y, Kan T, Yamamoto G, Olaru A, Kawamata N, Boult J, Soukiasian HJ, Miller CW, Ogawa S, Meltzer SJ, Koeffler HP.

Int J Cancer. 2009 Nov 15;125(10):2349-59. doi: 10.1002/ijc.24620.

10.

Hereditary Factors in Esophageal Adenocarcinoma.

van Nistelrooij AM, Dinjens WN, Wagner A, Spaander MC, van Lanschot JJ, Wijnhoven BP.

Gastrointest Tumors. 2014 Jun;1(2):93-8. doi: 10.1159/000362575. Epub 2014 May 9. Review.

11.

Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma.

Smith E, De Young NJ, Pavey SJ, Hayward NK, Nancarrow DJ, Whiteman DC, Smithers BM, Ruszkiewicz AR, Clouston AD, Gotley DC, Devitt PG, Jamieson GG, Drew PA.

Mol Cancer. 2008 Oct 2;7:75. doi: 10.1186/1476-4598-7-75.

12.

Overexpression of CD55 from Barrett's esophagus is associated with esophageal adenocarcinoma risk.

Murao T, Shiotani A, Fujita Y, Yamanaka Y, Kamada T, Manabe N, Hata J, Nishio K, Haruma K.

J Gastroenterol Hepatol. 2016 Jan;31(1):99-106. doi: 10.1111/jgh.13055.

PMID:
26202380
13.

Myo9B is associated with an increased risk of Barrett's esophagus and esophageal adenocarcinoma.

Menke V, Van Zoest KP, Moons LM, Pot RG, Siersema PD, Kuipers EJ, Kusters JG.

Scand J Gastroenterol. 2012 Dec;47(12):1422-8. doi: 10.3109/00365521.2012.722673. Epub 2012 Sep 7.

PMID:
22954106
14.

Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma.

Casson AG, Zheng Z, Evans SC, Geldenhuys L, van Zanten SV, Veugelers PJ, Porter GA, Guernsey DL.

Cancer. 2005 Aug 15;104(4):730-9.

15.

Epigenetic biomarkers in esophageal cancer.

Kaz AM, Grady WM.

Cancer Lett. 2014 Jan 28;342(2):193-9. doi: 10.1016/j.canlet.2012.02.036. Epub 2012 Mar 7. Review.

16.

Predictive value of MicroRNAs in the progression of barrett esophagus to adenocarcinoma in a long-term follow-up study.

Revilla-Nuin B, Parrilla P, Lozano JJ, de Haro LF, Ortiz A, Martínez C, Munitiz V, de Angulo DR, Bermejo J, Molina J, Cayuela ML, Yélamos J.

Ann Surg. 2013 May;257(5):886-93. doi: 10.1097/SLA.0b013e31826ddba6.

PMID:
23059500
17.

The Barrett-associated variants at GDF7 and TBX5 also increase esophageal adenocarcinoma risk.

Becker J, May A, Gerges C, Anders M, Schmidt C, Veits L, Noder T, Mayershofer R, Kreuser N, Manner H, Venerito M, Hofer JH, Lyros O, Ahlbrand CJ, Arras M, Hofer S, Heinrichs SK, Weise K, Hess T, Böhmer AC, Kosiol N, Kiesslich R, Izbicki JR, Hölscher AH, Bollschweiler E, Malfertheiner P, Lang H, Moehler M, Lorenz D, Ott K, Schmidt T, Nöthen MM, Hackelsberger A, Schumacher B, Pech O, Vashist Y, Vieth M, Weismüller J, Knapp M, Neuhaus H, Rösch T, Ell C, Gockel I, Schumacher J.

Cancer Med. 2016 May;5(5):888-91. doi: 10.1002/cam4.641. Epub 2016 Jan 18.

18.

Comparison of cancer-associated genetic abnormalities in columnar-lined esophagus tissues with and without goblet cells.

Bandla S, Peters JH, Ruff D, Chen SM, Li CY, Song K, Thoms K, Litle VR, Watson T, Chapurin N, Lada M, Pennathur A, Luketich JD, Peterson D, Dulak A, Lin L, Bass A, Beer DG, Godfrey TE, Zhou Z.

Ann Surg. 2014 Jul;260(1):72-80. doi: 10.1097/SLA.0000000000000424.

19.

NcoI TNF-β gene polymorphism and TNF expression are associated with an increased risk of developing Barrett's esophagus and esophageal adenocarcinoma.

Menke V, van Zoest KP, Moons LM, Hansen B, Pot RG, Siersema PD, Kusters JG, Kuipers EJ.

Scand J Gastroenterol. 2012 Apr;47(4):378-86. doi: 10.3109/00365521.2011.650192. Epub 2012 Jan 16.

PMID:
22243485
20.

A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome.

Lanuti M, Liu G, Goodwin JM, Zhai R, Fuchs BC, Asomaning K, Su L, Nishioka NS, Tanabe KK, Christiani DC.

Clin Cancer Res. 2008 May 15;14(10):3216-22. doi: 10.1158/1078-0432.CCR-07-4932.

Supplemental Content

Support Center